Calcimedica reports third quarter 2024 financial results and provides clinical & corporate updates

Additional positive data, including a win ratio analysis, announced from carpo phase 2b trial of auxora™ in acute pancreatitis (ap); company expects to be in a position to initiate phase 3 program in 2025 enrollment ongoing in phase 2 kourage trial in acute kidney injury (aki) and in phase 2 portion of crspa trial in asparaginase-induced pancreatic toxicity (aipt); data from both trials expected in 2025 following a public offering in october, the company's cash position is expected to fund current operations into the first half of 2026 la jolla, calif. , nov. 13, 2024 /prnewswire/ -- calcimedica inc. ("calcimedica" or the "company") (nasdaq: calc), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (crac) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported financial results for the third quarter ended september 30, 2024 and provided clinical and corporate updates.
CALC Ratings Summary
CALC Quant Ranking